Imdevimab API is a pharmaceutical-grade recombinant human IgG1 monoclonal antibody designed to specifically bind to the spike protein receptor-binding domain (RBD) of SARS-CoV-2, preventing viral attachment and entry into human cells. It has been used in combination with Casirivimab as an antibody cocktail for the treatment of susceptible COVID-19 infections and has also been evaluated for post-exposure prophylaxis.
As a highly specific neutralizing monoclonal antibody, Imdevimab is manufactured using advanced recombinant biotechnology processes to ensure high biological activity, purity, and consistency for biopharmaceutical applications.
Swapnroop Drugs and Pharmaceuticals manufactures Imdevimab API under stringent WHO-GMP quality systems. Every batch undergoes rigorous analytical and biological testing to ensure purity, potency, sterility, and regulatory compliance. Comprehensive documentation including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications is provided.
Imdevimab API is used in the development and manufacture of recombinant monoclonal antibody formulations for antiviral therapeutic applications.
Imdevimab binds to the receptor-binding domain of the SARS-CoV-2 spike protein, blocking viral attachment and preventing entry into host cells.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation.
Yes. We supply Imdevimab API in commercial quantities with worldwide export support, subject to applicable regulatory requirements.
Get Bulk Quote via WhatsApp